Movement Disorders

Take a look at some of the most-anticipated clinical trials with expected data readouts in the second half of 2024 that researchers and clinicians in neurology should keep an eye out on.

After 6 months of treatment, nearly half of the small-scale cohort demonstrated enhancements on the Unified MSA Rating Scale, an assessment of activities of daily living.

The neurologist and clerkship director at the University of Connecticut provided perspective on the developing role of clerkship directors and the value they provide to neurology departments.

The neurologist and director of movement disorder neurology at the Marcus Neuroscience Institute discussed how the Syn-One test utilizes alpha-synuclein and what this biomarker adds to the diagnosis of Parkinson disease. [WATCH TIME: 3 minutes]

Secondary symptoms of PD can be as debilitating as the primary motor symptoms, often leading to increased disability, reduced independence, and a higher burden on caregivers.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending July 20, 2024. [WATCH TIME: 4 minutes]

Neurology News Network. for the week ending July 13, 2024. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on multiple system atrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 12, 2024.

Recruitment has begun for Part C of the study, with topline data from this part of the trial expected to report in Q2 2025.

The associate professor of neurology at Georgetown University Medical Center talked about innovative treatments for dementia in movement disorders that target multiple mechanisms to effectively modify the disease. [WATCH TIME: 7 minutes]

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about a recent survey highlighting why patients with movement disorders may withhold critical health information from their providers.

The data, which comes less than a month after the FDA granted RMAT designation, highlighted the impacts of AMT-130 on disease progression in Huntington disease.

Most treatment-emergent adverse events for patients on UB-312 were mild or moderate, and comparable to placebo.

Catch up on any of the neurology news headlines you may have missed over the course of June 2024, compiled all into one place by the NeurologyLive® team.

The associate professor of neurology at Georgetown University Medical Center talked about the potential of tyrosine kinase inhibitors in treating neurodegenerative diseases. [WATCH TIME: 7 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The executive director of the Association of Movement Disorder Advanced Practice Providers discussed how effective patient care in movement disorders can lead to better management and treatment outcomes. [WATCH TIME: 4 minutes]

The nurse practitioner at the Cleveland Clinic talked about findings from a recent study focused on enhancing medication management and education for patients with Parkinson disease. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending July 6, 2024. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on headache and nerve decompression surgery.

The movement disorder specialist at Texas Movement Disorder Specialists talked about the complexities and advancements in treating Parkinson disease, emphasizing the need for strategic and aggressive treatment approaches despite administrative burdens. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 5, 2024.

The director of movement disorders at the Banner Sun Health Research Institute talked about making strides in developing minimally invasive tests and imaging ligands for neurodegenerative diseases, such as Parkinson disease. [WATCH TIME: 2 minutes]

The assistant clinical professor of medicine at Medstar Georgetown University Hospital highlighted the need for clinicians to maintain informed, open-minded discussions about therapeutic options. [WATCH TIME: 2 minutes]

Over the 3-year treatment period, buntanetap resulted in improvements in motor and nonmotor functions in patients with postural instability and gait difficulty, a group with faster disease progression.

Recent results from the SELECT-HD trial showed that WVE-003 was generally safe and had a well-tolerated profile in a 30 mg multidose cohort of patients with Huntington disease.

The neurologist and director of movement disorder neurology at the Marcus Neuroscience Institute provided an in-depth explanation of how the Syn-One test is used to help detect patients with Parkinson disease and related disorders. [WATCH TIME: 5 minutes]

Suvecaltamide did not meet the primary endpoint in the phase 2b trial but showed numeric improvements and was well-tolerated.